Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)
Johnson University · Washington Hospital · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
266
total citations
- FWCI
- 23.83
- Percentile
- 100%
- References
- 30
Citations per year
Authors
14Topics & keywords
Topics
Keywords
- Medicine
- Colistin
- Sulbactam
- Internal medicine
- Acinetobacter baumannii
- Imipenem/cilastatin
- Population
- Carbapenem
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.